Author, as appears in the article.: Masana L, Plana N, Pérez-Calahorra S, Ibarretxe D, Lamiquiz-Moneo I, Pedro-Botet J, Suárez-Tembra M, Valdivielso P, Ortega E, Civeira F, Dyslipidemia Registry of the Spanish Arteriosclerosis Society
Department: Medicina i Cirurgia
URV's Author/s: Ibarretxe Gerediaga, Daiana / Masana Marín, Luis / Plana Gil, Núria
Keywords: Pcsk9 Lipid lowering therapy Ldl target Familial hypercholesterolemia Evolocumab Alirocumab lipid lowering therapy ldl target familial hypercholesterolemia evolocumab alirocumab
Abstract: Familial hypercholesterolemia (FH) is a high cardiovascular risk condition. Less than 20% of patients achieve the LDL targets. Although PCSK9 inhibitors improve control and reduce cardiovascular events, official recommendations for their use are restrictive. We aim to assess the number of FH patients suitable for PCSK9 inhibition according to the European guidelines.A total of 2685 FH patients, with a minimum follow-up of 6 months, included in the Dyslipidemia Registry of the Spanish Arteriosclerosis Society, were sorted according to the intensity of their lipid-lowering therapy (LLT) and LDL cholesterol levels achieved. The number of patients who met the recommendations for PCSK9 inhibition treatment according to the European Atherosclerosis Society (ESC/EAS), Spanish Arteriosclerosis Society and the European Medicines Agency was calculated.In total, 1573 patients were on high-intensity LLT; 607 were on moderate-intensity statins; 82 were on low-intensity LLT, and 423 were neither on statins nor on ezetimibe in the last visit registered. The mean LDL reduction among those on high-intensity LLT was 54%. Ninety-one percent of patients on high-intensity LLT had an LDL below 5.2 mmol/L, 53% below 3.4 mmol/L, and 23% below 2.6 mmol/L. Only 12% of FH patients with cardiovascular disease achieved 1.8 mmol/L. Despite this, only 17% of patients qualified for PCSK9 inhibition according to ESC/EAS guidelines.For patients with a condition that exposes them to high cardiovascular risk and who have extreme difficulties in achieving LDL targets, wider access to PCSK9 inhibitor therapy is warranted.Copyright © 2017 Elsevier B.V. All rights reserved.
Thematic Areas: Saúde coletiva Psicología Peripheral vascular disease Odontología Nutrição Medicina iii Medicina ii Medicina i Interdisciplinar General medicine Farmacia Engenharias ii Enfermagem Educação física Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciência de alimentos Ciência da computação Cardiology and cardiovascular medicine Cardiac & cardiovascular systems Biotecnología Antropologia / arqueologia
licence for use: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 00219150
Author's mail: daiana.ibarretxe@urv.cat nuria.plana@urv.cat luis.masana@urv.cat
Author identifier: 0000-0002-4231-7618 0000-0002-0789-4954
Record's date: 2023-02-18
Papper version: info:eu-repo/semantics/acceptedVersion
Link to the original source: https://www.atherosclerosis-journal.com/article/S0021-9150(17)30216-2/fulltext
Licence document URL: http://repositori.urv.cat/ca/proteccio-de-dades/
Papper original source: Atherosclerosis. 262 107-112
APA: Masana L, Plana N, Pérez-Calahorra S, Ibarretxe D, Lamiquiz-Moneo I, Pedro-Botet J, Suárez-Tembra M, Valdivielso P, Ortega E, Civeira F, Dyslipidemia (2017). How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?. Atherosclerosis, 262(), 107-112. DOI: 10.1016/j.atherosclerosis.2017.05.013
Article's DOI: 10.1016/j.atherosclerosis.2017.05.013
Entity: Universitat Rovira i Virgili
Journal publication year: 2017
Publication Type: Journal Publications
Repositori URV